Upon conclusion of this program, participants should be able to:

• Identify approaches to therapy for localized gastroesophageal cancer
• Describe approaches to localized therapy for pancreaticobiliary cancers
• Recognize new therapy options for colorectal cancer
• Describe the role of the new JAK2 inhibitors in the management of myeloproliferative disorders
• Identify how the new molecular markers in acute myeloid leukemia can influence treatment options
• List systemic therapies for GIST in the metastatic and adjuvant settings
• Describe commonly used strategies for systemic therapy for soft tissue and bone sarcomas
• Recognize risk/benefits of the current treatment options for castrate resistant metastatic prostate cancer
• Review current treatments for metastatic renal cancer and formulate a plan for each individual patient
• Recognize the importance of risk stratification in myeloma and CLL and its impact on therapeutic decisions
• List the most important clinically relevant research findings in 2011-2012 in the areas of hematology and medical oncology

Attendance at this Mayo course does not indicate nor guarantee competence or proficiency in the performance of any procedures which may be discussed or taught in this course.